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Summary Recent circumstantial evidence has implicated Insulin-like growth factor II in the genesis of several
tumour types, notably developmental tumours (Scott et al., 1985; Schofield & Tate, 1987; Wilkins et al., 1989).
This type of tumour, thought to originate during the defective differentiation of organ precursors (Miereau et
al., 1987), often expresses greatly elevated levels of mRNA for IGF-II, a known mitogen for these cells and
abundantly expressed in their presumed normal counterparts (Scott et al., 1985; Schofield & Tate, 1987; Gray
et al., 1987). It has been proposed that continued, inappropriate expression of this gene drives tumour growth
by an autocrine mechanism. In order to examine the potential role of IGF-II in the growth of tumour cells an
IGF-Il cDNA was introduced into a retroviral expression vector, and used to infect a cloned fibroblast cell
line. Expression of IGF-II conferred a degree of serum independence of growth in cell culture, however, when
cells were injected into nude mice as subcutaneous grafts, clones expressing IGF-II from the retrovirus were
found to have a greatly increased (five fold) latency of sarcoma formation. After a prolonged lag all cell lines
eventually gave rise to tumours in which the introduced IGF-II genes had either been lost or inactivated,
suggesting that in this system IGF-I1 acts as a tumour suppressor gene.
The Insulin-like growth factors I and II are peptides of 70
and 67 amino acids respectively which show a wide variety of
biological actions on a large range of target cells. These
include effects on proliferation as well as the induction and
support of differentiation in many foetal and embryonic cell
types. In humans the IGF-II gene is maximally active during
the foetal period in specific rapidly proliferating cell types,
amongst which are fibroblasts, hepatocytes, metanephric
blastema cells and cells of the foetal adrenal cortex (Gray et
al., 1987; Brice et al., 1989; Han et al., 1987; 1988). Because
many of these cell types are known to respond to the growth
factor in 'primary culture (e.g. Hill et al., 1986; 1987) auto-
crine and paracrine mechanisms have been suggested as the
natural mode of action in these tissues. Transcription of the
IGF-II gene in the foetus is driven from a trio of distinct
promoters which are used in specific ratios in different tissues
(Schofield & Tate, 1987; dePagter-Holthuizen et al., 1987;
reviewed, Sussenbach, 1989). The basis of these different
ratios is unknown, but all three promoters are profoundly
suppressed (50-100 fold) as development and histogenesis
proceed.
In many naturally occurring and experimental neoplasms
the 'foetal' promoters of IGF-II are 'reactivated'. This obser-
vation is particularly striking in the case of a group of
developmental neoplasms, hepatoblastoma, embryonal neph-
roblastoma (Wilms' tumour), adrenocortical carcinoma and
rhabdomyosarcoma (Scott et al., 1985), but elevated expres-
sion is also seen in hepatocellular carcinoma (Su et al., 1989;
Cariani et al., 1988), leiomyoma & leiomyosarcoma (Hop-
pener et al., 1988; Daughaday et al., 1988), colon carcinoma,
and liposarcoma (Tricoli et al., 1986) together with fibrosar-
comas (Schofield et al., 1989). One common feature of all
these tumours is that the presumed foetal counterparts of all
these cell types make significant quantities of IGF-II mRNA
and protein (Han et al., 1988; Hill, 1990) while their normal
adult counterparts do not. In situ hybridisation analysis of
human foetal kidney formation (Brice et al., 1989) supports
the view that the expression of high levels of IGF-II by the
blastema component of Wilm's tumour reflects the pattern of
gene expression in bonafide blastema during the developmen-
tal window during which the tumour is thought to arise.
Similar arguments may be made for both hepatoblastoma and
adrenal cortical carcinoma. (See Schofield 1991 for review).
Because autocrine growth is thought to operate in the
normal foetal counterpart it has been suggested that the
reactivated or continued expression of the IGF-II gene in
these tumours is responsible for driving cell proliferation in
an autocrine fashion. In order to test whether IGF-II might
act as an autocrine stimulator of tumour growth, we ana-
lysed the effects of IGF-I1 expression on tumour formation




Balb/c/3T3 fibroblasts (clone A 31) (Todaro & Green, 1963)
were obtained from the Sir William Dunn School of Path-
ology collection, cultured in a 50/50 mixture of Alpha
modified Eagles medium/Ham's F12 (Alpha/Ham) supp-
lemented with 10% heat inactivated foetal calf serum
(Seralabs) and cloned into microtiter plates by single cell
picking following mitotic shake off from subconfluent cul-
tures. Several 'parental' clones were picked on the basis of
flat, 'normal looking' morphology, expanded, and one
selected for infection with retrovirus supernatents. Balb/c
(1-3) are sister clones, from the same bulk population, which
do not express IGF-II from their own endogenous gene,
Balb/c (1) is the parent clone used for infection with virus.
Infection and cloning of virus carrying lines was carried out
essentially as described in Boulter and Wagner, (1988)
5 x 104 Balb/c cells were plated onto 60 mm diameter dishes
(Nunc) in Alpha/Ham/10% foetal calf serum and infected
with virus bearing cellular supernatent. Clones resistant to
800 ig ml-' G418 (GIBCO UK Ltd.) were isolated after 14
days and expanded using a 3T3 regime. BB4, Ball2, Bal9 and
Bal4 were all clonal cell lines selected on the basis of produc-
tive construct expression.
For growth experiments cells were plated out onto 60 mm
diameter Primaria (Falcon, Beckton-Dickinson, New Jersey,
USA) dishes in Alpha/Ham/10% foetal calf serum. After
attaching overnight they were washed 5 x in serum free
medium and overlaid with 5 ml of Alpha/Ham containing
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0.5% foetal calf serum. Cell numbers were then counted daily
in triplicate in parallel dishes over the remaining 13 days.
IGF-II secretion was measured by plating 5 x 105 cells in
90 mm petri dishes in a 50/50 mixture of Alpha modified
Eagles medium/Hams F12 (Alpha/Ham) supplemented with
1Ofig ml-' transferrin and 10% foetal calf serum (Biddle et
al., 1988). Subconfluent cells were washed and overlaid with
5 ml of the same medium as above but lacking foetal calf
serum. Medium was collected after 16 h and subjected to
extraction and radioimmunoassay according to Hill et al.
(1989).
Tumourigenicity assays
5 x 106 cells in phosphate buffered saline harvested from
subconfluent cultures by treatment with trypsin/versine (Bern-
stine et al., 1973) were injected subcutaneously over the
scapula of nude mice in a volume of0.1 ml. In all experiments
presented, 6 week old Balb/c nu/nu mice were used, five mice
per graft. In parallel experiments similar results were obtained
using CBA nu/nu Y and outbred nu/nu Y with five mice per
cell line. In a separate experiment (see Table I) 5 x 106 BB4
cells were mixed with 5 x 106 Antisense construct containing
cells before inoculation into a single suprascapular site.
Balb/c nu/nu mice were obtained from the MRC Clinical
Research Centre, Harrow, others were bred in house. All
experiments were carried out according to the Medical Re-
search Council UKCCR guidelines. Mice were fed ad libitum
during the experiment and palpated daily. 'Latency' repre-
sents the time taken from grafting to the first palpable
growth of around 1 mm3 (estimated with calipers) and the
experiments continued for 18 months in the case of the single
animal which did not show a tumour.
Viral constructs
A human IGF-II cDNA was derived from the hepatoma cell
line previously described (Schofield & Tate, 1987). This
variant cDNA contained a polymorphism in the B domain of
the peptide converting glu-6 to gly-6. The cDNA was cloned
into the Bgl II site of the replication defective retroviral
vector pXTI (Boulter & Wagner, 1990) by linker substitution
such that the IGF-II cDNA was driven from the HSV TK
promotoer. Genomic and spliced genomic transcripts (mark-
ed g and sg respectively in Figure 1), give rise to the product
of the neo gene and the TK driven transcripts to IGF-II
protein. Viral genomes were transfected into the packaging
line PA317, and G418r clones selected as viral producers for
infection of the ecotropic packaging line Psi-2 (Mann et al.,
1983). G418' clones of psi-2 were then selected for produc-
tion of retrovirus. The line used produced 0.5 x I05 cfu ml-',
when titred on Balb/c fibroblasts. All cell clones infected with
IGF-II carrying retrovirus used in the grafting experiments
were found to be free of helper virus.
Xbal Eco Rl Eco Rl Xbal




Figure 1 A human IGF-II cDNA was derived from the hepa-
toma cell line HEP-G2 as described in Materials and methods
and cloned into the Bgl-II site of the replication defective vector
pXTJ by linker substitution such that the IGF-II cDNA was
driven from the HSV TK promoter. Genomic and spliced
genomic transcripts (marked g and sg respectively), give rise to
the product of the neor gene, and the TK driven transcripts to
IGF-II protein.
Expression ofretroviral constructs in Balblcfibroblasts
5 x 104 Balb/c cells were plated onto 60 mm dishes in Alpha/
Ham/10% foetal calf serum and infected with virus bearing
cellular supernatent as described previously. Clones resistant
to 800figmlm' G418 were isolated after 14 days and ex-
panded. Polyadenylylated RNA was prepared from sub-
confluent cultures, electrophoresed on denaturing for-
maldehyde gels and blotted to nitrocellulose.
Nucleic acidanalysis
Polyadenylylated RNA was prepared from subconfluent cul-
tures by treatment with protease K and batch adsorbtion
onto oligo dT cellulose (Pharmacia) according to Boulter &
Wagner (1988), electrophoresed on denaturing formaldehyde
gels and blotted to nitrocellulose (Lehrach et al., 1977).
Filters were hybridised to an IGF-II probe derived from the
parent construct. Markers were an RNA ladder purchased
from BRL Ltd, and positions shown above. Provirus copy
number was estimated by digestion of genomic DNA from
clones with Xhol and subsequently hybridisation with the
neor gene probe (Coulombe & Skup, 1986). Control hy-
bridisation was carried out using a mouse alpha-globin probe
kindly provided by Dr Emma Whitelaw (Whitelaw et al.,
1989).
Results
Effects ofexpression ofIGF-II in vitro
A human IGF-II cDNA was isolated from a hepatoma cell
line, Hep G2, and cloned into the BglII site of the retroviral
vector pXTI, as described in Materials and methods. Viral
genomes were packaged in the ecotropic packaging cell line
psi-2 and used to infect a cloned subline of Balb/c/3T3
fibroblasts (Balb/c (1)). G418 resistant colonies resulting were
cloned and characterised, and four clones were chosen which
expressed the introduced gene at different levels. Clones bear-
ing a construct with the IGF-II gene inserted 3'-5' with
respect to the HSV Thymidine Kinase (TK) promoter were
similarly obtained and were designated 'antisense' constructs
(see legend to Figure 1). Levels of mRNA from the internal





Figure 2 Expression of retroviral constructs in Balb/c clones.
Filters were hybridised to an IGF-II probe derived from the
parent construct. Markers were an RNA ladder purchased from
BRL Ltd, and positions shown above. BB4, Ball2, Bal9 and Bal4
were all clonal cell lines selected on the basis of productive
construct expression. Balb/c is the parent clone, Balb/c (1), which
does not express IGF-II from its own endogenous gene.
Genomic, spliced genomic and transcripts originating from the
TK promoter are marked as g, sg and TK respectively.TUMOUR SUPPRESSION ASSOCIATED WITH IGF-II 689
TK promotor, which are the only species capable of transla-
tion into IGF-II peptide, were generally low in comparison
with the LTR derived genomic transcripts (see Figure 2), but
radioimmunoassay showed that the cells with the 'sense'
constructs secreted IGF-II into tissue culture supernatent
(Table I). No correlation was seen between the morphology
of individual clones and the levels of secreted protein.
The effect of expression of IGF-II on cell growth in culture
was assayed by transfer to 0.5% serum containing medium,
and by counting cell numbers over the next 14 days (see








Figure 3 Effects of expression of IGF-II on growth of infected
clones and controls under conditions of serum starvation.a, 0;
Balb/c (1), control cell line, *;Balb/c supplemented with lOng
ml-' recombinant human IGF-IIdaily. b, Ball2, c, 0; Bal9, 0;
Bal4. d, BB4. Cell numbers were counted daily in triplicate in
parallel dishes over the remaining 13 days. Each point is the
result of four replicates for each experiment.
ing IGF-II at levels >6 ng/106 cells/24 h assumed a more
flattened aspect, wherease the control cell lines were much
more refractile and poorly attached. This difference was only
seen on serum starvation. Growth of control cells over the
first 8 days was slower than those making IGF-II, and the
control cells reached a much lower density after 14 days:
1.17 x 104cm-2 as opposed to 5 x 10 cm-2 for the most
rapidly growing. Supplementation of the medium of control
cells with 10 ng ml-' of human recombinant IGF-II (Eli
Lilley) daily showed a marked recovery in the rate ofpopula-
tion growth similar to that obtained by autocrine expression
(Figure 3a). We conclude that the expression of IGF-II by
clones of the Balb/c/3T3 cell line aids their growth under
conditions of serum starvation.
Effects ofIGF-II expression on growth ofgrafts in nude mice
Grafting of four experimental cell lines, and four control
lines (the parental clone (Balb/c (1), two sister clones (Balb/c
(2) and (3)) derived at the same time but not infected with
the virus, and an antisense construct containing clone) show-
ed unexpectedly, that growth of cells bearing IGF-II con-
structs in nude mice was dramatically inhibited. (Table I).
Cells (5 x 106) were inoculated subcutaneously over the scap-
ula of Balb/c nu/nu mice. The site of injection was palpated
daily and the latency of tumour formation estimated by the
time taken for a noticeable nodule to form (generally about
1 mm in diameter). Thereafter tumour size was estimated by
caliper measurements and the experiments terminated when
the tumour reached a weight of approximately 1 g. The
longest mean latency observed was 76.2 days. Once tumours
were detected, the average increase in weight from first palpa-
tion to harvest was almost identical for all groups at
20mgday-' ± 0.04 mg (s.d.). Tumour histology at 2 weeks
showed small nests of undifferentiated cells, while primitive
fibrosarcomas dominated the tumours at the end of the
experiment. Little difference between the cell lines was appar-
ent, either in terms of vascularisation or differentiation, but
tumours dervied from cells which originally expressed IGF-II
did show approximately 50% more mitotic figures per field
than controls when examined at the end of the experiment.
We attempted to establish cell lines from tumours, both in
the presence and absence of 800 g ml-' G418, and then
analysed DNA and RNA from them. Surprisingly G418
resistant cell lines were difficult to obtain from experimental
tumours whose progenitor cells were G418r. Analysis of
DNA and RNA from both primary tumours and cultures
established without G418 present indicated that in the major-
Table I Effects of IGF-II expression on tumour formation in nude
mice
Intact IGF-II
provirus copy secretedl Latency Tumour take
Graft number 10J cells/24h (days±s.d.) incidence
Balb/c (1) 0 0 14.75±3.8 8/8
Balb/c (2) 0 0 17.5±2.3 5/5
Balb/c (3) 0 0 12.5±1.2 5/5
Bal9 1 5.9 14.7±4.2 10/10
Bal4 1 8.2 61.7±5.0 10/10
BB4 1 11.0 76.2±10.0 10/10
Ball2 1 12.7 54.1±3.8 9/10
Antisense I 0 12.0±2.0 10/10
BB4/Anti- 1/0 11.0/0 16.1±3.1 5/5
sensea
Balb/c (1) represents the parental cloned cell line, Balb/c (2), and
Balb/c (3) cell lines cloned from the same population as Balb/c (1) but
not used for expression. Bal9, Bal4, Bal2 and BB4 individual clones
infected with IGF-IIexpressing retroviruses, and Antisense, a clone
carrying a retrovirus with the IGF-IIcDNA in reverseorientation with
respect totheTKpromoter..BB4/Antisensearepresentsthedatafroman
experiment in which 5 x 106 BB4 cells were mixed with 5 x 106
Antisenseconstructcontainingcellsbeforeinoculationinto asinglesite.
Groups offive mice were used foreachexperimental set as described in
Materials and methods.690 P.N. SCHOFIELD et al.
ity of cases (35/40) the tumour cells had lost the active
introduced copies of the virus (see Figure 4). Of the remain-
ing five cases the IGF-Il sequences were truncated in one
instance, did not produce mRNA transcripts (e.g. XG7 in
Figure 4), presumably due to point mutations, in two cases,
since no change in the restriction map was evident; and
unaffected in the two remaining tumours. From these results
it is clear that Bal 9 is unusual in that it loses the IGF-II
sequences very rapidly (see Table I). Karyotype analysis was
conducted on cell lines established from tumours in the
absence of G418 selection, and demonstrated no consistent
pattern of chromosome loss or gain during the latent period.
IGF-II is usually active as a secreted peptide and we
wished to see if it were possible to obtain a trans-acting
suppression of tumour formation by mixing equal numbers
of an IGF-II expressing clone (BB4) with the antisense con-
taining line. 5 x 106 cells of each line were inoculated supra-
scapularly into a single site. The results are shown in Table I,
and indicate that no obvious trans acting effect could be
obtained.
Discussion
It has previously been reported that Balb/c/3T3 fibroblasts
require insulin-like growth factors to proliferate under condi-
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Figure 4 Pattern of construct retention and loss from three
representative sets of allograft tumors derived from retrovirally
infected cells lines. a, Balb/c; parental cell line, Antisense; clonal
cell line containing proviral construct with IGF-II cDNA in
antisense orientation with respect to TK promoter. XGl-XG9 are
allograft tumour DNAs derived from the antisense clone. b,
Bal12; clonal cell line containing IGF-IIexpressing proviral con-
struct, XG1-XG-7, allograft tumours derived from Bal12 after
extended latency. Bal4; clonal cell line containing IGF-IIexpress-
ing proviral construct. XG8-XG9; representative allografts
derived from Bal4; c filter b reprobed with the mouse a-globulin
gene probe derived from MpSVod. (28). The markers used were
an HindII/EcoRl digest of bacteriophage lambda.
pendence is not only reflected in their rate of proliferation
but also in their ability to grow in an anchorage independant
fashion (Massague et al., 1985). We confirm these findings
and have demonstrated that this requirement may be abro-
gated by provision of endogenously synthesised peptide.
Addition of exogenous recombinant IGF-II to non-expres-
sing cells stimulated cell proliferation markedly but seemed
to be less effective than autocrine expression in sister clones
in terms of nominal available concentration/cell when com-
pared with the measured rates of secretion of IGF into the
medium. This may be explained by continuous internalisation
of autocrine IGF-II during growth, leading to an underes-
timate of the rate of production.
The three parental clones from our original population of
target cells were of similar morphology, and little variability
was observed in their ability to produce tumours in nude
mice. This is broadly in agreement with previous studies
(Rubin, 1988) though less clonal variability in tumouri-
genicity was seen in the experiments described here. Surpris-
ingly, whilst an autocrine growth loop was apparently oper-
ating in the cells in vitro, expression of IGF-II acted to
suppress tumour formation in vivo. Loss of the introduced
construct in the majority of the experiments suggests that the
expression of IGF-II is strongly selected against during
tumour formation in immunodeprived mice and by this
criterion IGF-II is a tumour suppressor gene. The suppres-
sive effect in vivo probably relies on an interaction between
graft and host, because expression acts to promote cell
growth in vitro (Figure 3). We consider it unlikely that there
was extensive host contribution to the tumours, because the
relative copy number of viral sequences in the tumours
derived from antisense constructs was always commensurate
with that seen in the inoculated cells. The karyotypes of cell
lines derived from the tumours were clearly not of host
origin, and resembled those of the injected cells, without any
general pattern of chromosome loss. These results are consis-
tent with selection directed against cells expressing IGF-II
constructs, since cells with the antisense construct gave rise to
tumours within 14 days of grafting (10/10); all these tumours
retained the construct and, when explanted, readily gave rise
to G418' cultures. A similar pattern of construct loss from
grafts carrying presumptive tumour suppressor genes has also
been reported for the IL4 gene (Tepper et al., 1988). How-
ever, in contrast to the systemic effects of IL4 on tumour
suppression implantation of expressing and non-expressing
clones together did not result in a trans effect. This suggests a
cell autonomous process such as that described by Copeman
and Harris (1990).
Identification of IGF-II as a tumour suppressor in this
system is surprising because in the clinical situation levels of
IGF-II mRNA are often much higher in tumours than in the
surrounding adult host tissue in which they are found (Scott
et al., 1985, Su et al., 1989; Cariani et al., 1988; Hoppener et
al., 1988; Daughaday et al., 1988; Tricoli et al., 1986). In
general only the presence of mRNA has been examined and
few experiments have addressed the concurrent presence of
IGF-II peptide. This paradox may therefore be explained by
the operation of various mechanisms both acting to reduce
gene dosage and to regulate the production of bioactive
IGF-Il post transcriptionally. The results presented here sug-
gest that in some types of tumour the IGF-II genes should be
either reduced in dosage or altered in some way to produce
an IGF-II protein which does not promote tumour suppres-
sion.
In sporadic Wilms' tumour (Reeve et al., 1989), hereditary
Wilms; tumour, Beckwith-Weidemann syndrome (Ping et al.,
1989), adrenocortical carcinoma, rhabdomyosarcoma
(Koufos et al., 1985) and mammary carcinoma (Ali et al.,
1987) allele loss at llpl5.5 is frequently detected with allele
specific polymorphisms in the insulin gene, and these losses
are not always associated with detectable changes in the
more proximal region of the short arm. As the insulin gene is
only 1.4 kb 5' of the IGF-II locus, loss of an insulin allele is
almost certainly accompanied by loss of the adjacent IGF-II
locus. A reduction in IGF-II gene dosage or rearrangementTUMOUR SUPPRESSION ASSOCIATED WITH IGF-II 691
has also been found in such tumours (e.g. Irminger et al.,
1989) which would not be expected if selection were occurr-
ing in the tumour for autocrine growth based on high levels
of expression of bioactive IGF-II. Our results suggest that it
may be selective pressure for loss of the IGF-II gene at 1 lpl5
which fully or partially accounts for loss of this region of
chromosome 11 in naturally occurring tumours. A similar
result may be achieved by translational regulation, rather
than genetic loss or inactivation, and inhibition of translation
of IGF-II mRNA has recently been shown in several Wilms'
tumours (Haselbacher et al., 1987).
We propose that expression of IGF-II mRNA by develop-
mental tumours may be a tumour epiphenomenon, as the
postulated progenitor cell types, (e.g. metanephric blastema
in the case of Wilms' tumour), are known to make IGF-II
mRNA and protein at high levels. Selection against such
expression in a cell already transformed might be expected if
IGF-II has the same suppressive effect on tumour formation
in man as in an experimental situation. In support of this
Little et al. (1987) using xenografts of primary Wilms'
tumours, were able to demonstrate that IGF-II expression
was selected against during tumour passage, and they sug-
gested that elevated IGF-II mRNA was not an essential
component of tumour progression. Additionally, Maitland et
al. (1989) have reported the selective loss of chromosome 11
during maintenance of cell hybrids between normal human
foetal kidney and HeLa cells as grafts in nude mice. The
reported occurrence of deletions in llpl3 and llpl5 in
Wilms' tumours associated with aniridia (WAGR) (Henry et
al., 1989) suggests that suppression of IGF-II expression may
be important in tumour progression rather than in initiation,
the latter perhaps being the function of the llpl3 deletion.
Candidate genes in this region have recently been described
(Gessler et al., 1990; Rose et al., 1990). Current experiments
are being directed towards the mechanism responsible for the
tumour suppressing effect of IGF-II.
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